o2h Ventures is pleased to announce its recent investment from the o2h human health SEIS fund into Stratosvir, a company focusing on viral immunotherapy solutions for late-stage cancer.

16 April. Cambridge

The World Health Organisation (WHO) projects over 35 million new cancer cases by 2050, a staggering 77% increase from the estimated 20 million cases in 2022. Viral Immunotherapy can be a promising solution. It utilises viruses to target and replicate within tumour cells causing them to break down and die. The process also activates the immune system, helping it to identify and overcome immunosuppression caused by tumour cells.

The oncolytic viral space is gaining momentum with CG Oncology just having a successful IPO (oversubscribed and a doubling of share price). Stratosvir is developing viral immunotherapies for cancer, including allowing intravenous delivery and making it possible to dose multiple times. It combines in situ vaccination with multi-biologics delivery to systematically treat late-stage cancers. Stratosvir was formed through a collaboration between Cancer Research UK and Deep Science Ventures and has already made significant strides with a grant from Innovate UK.

To delve deeper into the important research that Stratosvir are undertaking in the field of cancer, please watch the company’s pitch video presentation. For more details, please reach out to

Sunil Shah, CEO of o2h Ventures, said:

“This is an experienced team with both commercial and scientific experience in the field of Oncolytic Viruses. Innovate UK awards are highly competitive, and we are pleased to be able to support the company with start-up funding.”

Dr.Christopher Ullman, CEO of Stratosvir, said:

“Stratosvir is delighted to welcome o2h on its quest to develop novel high-impact treatments for cancer patients. Viral immunotherapy is ‘coming of age’ and our unique approach, for systemically deliverable and immune-stimulating therapies, targets indications of high unmet need (e.g castrate-resistant prostate cancer). We are excited to work with such a pioneering early-stage investor to drive our transformative technology into clinical development, delivering meaningful benefit to cancer patients.”

About Stratosvir:
We passionately join cancer patients in their fight for effective, safe, non-toxic cancer treatments that increase quality of life and survival. As a weapon, we are developing viral immunotherapy which has the potential to drastically improve the clinical treatment of solid tumours and their metastases. To know more, please visit:

About o2h Ventures
The o2h Ventures ‘Human Health’ SEIS and EIS funds make tax-efficient investments in Pre-Seed and seed-stage companies that address human disease: we fund the development of novel therapeutic treatments; we help build new services and tools offerings throughout the biotech ecosystem, and we spur the creation of software & artificial intelligence that will change healthcare.

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.

For more information or to invest in the fund, please visit